Status:
COMPLETED
A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Glaucoma, Open-Angle
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the effect of latanoprost on intraocular pressure reduction in patients with ocular hypertension or open-angle glaucoma.
Eligibility Criteria
Inclusion
- A patient with an IOP greater than or equal to 20 mmHg related to unilateral or bilateral OH or OAG (primary open angle glaucoma, pseudo-exfoliative glaucoma, and pigmentary glaucoma), after a visual field exam
- Naive patients (i.e. never having been treated) and requiring treatment initiation
Exclusion
- A patient with OH or OAG currently on treatment
- A patient with OH or OAG previously treated (regardless of the date treatment was discontinued)
- A patient with traumatic, inflammatory, or neovascular glaucoma
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2005
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00647101
Start Date
December 1 2003
End Date
February 1 2005
Last Update
February 2 2021
Active Locations (176)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Albi, France, 81000
2
Pfizer Investigational Site
Ambert, France, 63600
3
Pfizer Investigational Site
Amboise, France, 37400
4
Pfizer Investigational Site
Angers, France, 49100